{"id":"W2889898143","doi":"10.1016/j.ejca.2018.08.002","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"Institut Gustave-Roussy; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Fulvestrant; Medicine; Internal medicine; Placebo; Oncology; Population; Cancer; Breast cancer; Adverse effect; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007819714,0.0006820375,0.0007999734,0.0001268426,0.0005354894,0.0001035659,0.0009026096,0.0001826563,0.0003784112],"category_scores_gemma":[0.000288617,0.000629156,0.0003639713,0.0001751934,0.0004701911,0.00008367992,0.000215418,0.0005378614,0.00002022795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005654686,"about_ca_system_score_gemma":0.0008759637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005027718,"about_ca_topic_score_gemma":0.0002853182,"domain_scores_codex":[0.9955767,0.0006293422,0.00134617,0.0009163259,0.0006883225,0.0008431352],"domain_scores_gemma":[0.995833,0.0002460602,0.001410996,0.0005245177,0.001483027,0.0005023435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06772991,0.0001083775,0.0001181936,0.00002995585,0.001142274,0.00004620949,0.0009979827,0.0007701091,0.9039598,0.00002224325,0.01894703,0.006127985],"study_design_scores_gemma":[0.08334006,0.01477043,0.02970237,0.0008877101,0.0006031809,0.00007043786,0.0004478608,0.0001047871,0.7710211,0.00005726334,0.09664326,0.002351503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771806,0.004885834,0.001157878,0.001399909,0.004324869,0.0006814722,0.009005761,0.00003763127,0.001326047],"genre_scores_gemma":[0.9851046,0.002739729,0.003050549,0.0003367155,0.007567279,0.00003243015,0.0003159306,0.0002110587,0.0006417721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1329386,"threshold_uncertainty_score":0.999616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02433777903888868,"score_gpt":0.2946554894638917,"score_spread":0.270317710425003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}